Skip to main content

Find Clinical Trials

Home
Conditions
Carcinoma, Medullary

Clinical trial condition

Carcinoma, Medullary

Explore clinical trials studying Carcinoma, Medullary. Study availability and eligibility vary by location and protocol.

103 public trials 12 recruiting studies

Refine in advanced search Browse all conditions

Carcinoma, Medullary trial results

Completed

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

NCT00519896

Conditions: Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +26 more
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

NCT00118248

Conditions: Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +22 more
Locations: Mayo Clinic Rochester, Minnesota, United States

View Trial Details

Completed

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

NCT00358956

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +17 more
Locations: Research Site Little Rock, Arkansas, United States

Research Site Boston, Massachusetts, United States

Research Site St Leonards, Australia

Research Site Sherbrooke, Quebec, Canada

View Trial Details

Completed

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

NCT01661179

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +14 more
Locations: Research Site Fukuoka, Japan

Research Site Kobe, Japan

Research Site Kōtoku, Japan

Research Site Shinjuku-ku, Japan

View Trial Details

Completed

Vandetanib Risk Minimisation Effectiveness

NCT01757470

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more
Locations: Research Site Montreal, Quebec, Canada

View Trial Details

Completed

Capecitabine and Temozolomide for Neuroendocrine Cancers

NCT00869050

Conditions: Adenocarcinoma, Carcinoid Tumor, Carcinoma, +32 more
Locations: Columbia University Medical Center New York, United States

View Trial Details

Completed

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476

Conditions: Adenocarcinoma, Adenoma, Adenoma, Islet Cell, +52 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT01155258

Conditions: Adenocarcinoma, Adnexal Diseases, Breast Diseases, +115 more
Locations: USC/Norris Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Completed

SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer

NCT01625520

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more
Locations: Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University of Naples Naples, Italy

View Trial Details

Completed

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

NCT01164176

Conditions: Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +20 more
Locations: Hallym University Sacred Heart Hospital Anyang, Gyeonggi-do, South Korea

Yeungnam University Medical Center Daegu, South Korea

National Cancer Center - Korea Goyang, South Korea

Kosin Medical Center Gospel Hospital Pusan, South Korea

View Trial Details